Summary
Category Scores
Accurate Statements
Unsupported Statements
Mounjaro (tirzepatide) wholesale pricing is commonly discussed using the list price known as WAC (Wholesale Acquisition Cost).
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
WAC (Wholesale Acquisition Cost) is set by the manufacturer.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
WAC can differ from what plans, pharmacies, and wholesalers actually pay after rebates and discounts.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
The exact WAC depends on the specific NDC/package strength and the most recent price update.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
The wholesale/list price varies by Mounjaro dose/pen strength.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
Mounjaro is sold in multiple dose strengths.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
The wholesale/list price generally varies by the specific NDC and package size.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
Drug pricing databases can provide the latest wholesale/list pricing by strength.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
Even when the wholesale/list price is identified, the amount different groups pay can be lower due to PBM rebates and negotiated discounts.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
The amount different groups pay can be lower due to insurer contracts and formulary placement.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
The amount different groups pay can vary due to different handling of branded versus specialty distribution channels.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
Patient-specific factors such as coverage, copays, and manufacturer programs can affect what patients pay.
Not supported or addressed by the provided prescribing information sections (thyroid C-cell tumor/MTC risk).
Contradictions
Important Omissions
Any statements addressing the FDA label’s MTC/thyroid C-cell tumor risk content for MOUNJARO (e.g., rodent findings and human relevance unknown, contraindication in patients with personal/family history of MTC or MEN 2, patient counseling on thyroid tumor symptoms, and monitoring uncertainty).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because the provided AI content does not include any on-label MTC/thyroid C-cell tumor risk information, required risk communication and contraindication context from the label are omitted for the asked claim area.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
The AI-generated statements are unrelated to the FDA label sections governing thyroid C-cell tumor/MTC risk and provide no label-supported risk/contraindication/counseling information.
Suggested Improvement
Replace the pricing discussion with explicit, label-grounded statements from sections 5.1 (Risk of Thyroid C-Cell Tumors), 4 (Contraindications), and 17 (Patient Counseling Information), including: rodent findings, unknown human relevance, contraindication for MTC/MEN 2, symptom counseling, and the uncertainty of routine calcitonin/ultrasound monitoring value.